Thomas Björk

3.9k citations
35 papers · 2.8k · 2 hit papers · h-index 22

Impact in

    • Prostate Cancer Treatment and Research
    • Prostate Cancer Diagnosis and Treatment
    • Lung Cancer Treatments and Mutations
  • Oncology top 5%
    • HER2/EGFR in Cancer Research
    • Colorectal Cancer Treatments and Studies

Papers in

Thomas Björk

32 papers receiving 2.7k citations

Hit Papers

Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types 2002 · 683 citations
6830+11+22Years since publication200400600

Peers

Thomas Björk
Comparison fields: 5 of 110
  • Pulmonary and Respiratory Medicine 2.0k
  • Oncology 787
  • Rheumatology 394
  • Urology 156
  • Statistics and Probability 132
Replace Gerrit Draisma with:
Gerrit Draisma Netherlands
Alan R. Hay United States
Thierry Gil Belgium
William J. Catalona United States
Axel Semjonow Germany
Eli Rosenbaum Israel
Raymond S. Lance United States
Danny Vesprini Canada
Robert B. Den United States
Leslie A. Mangold United States
Thomas Björk relative to Gerrit Draisma Netherlands Gerrit Draisma's profile →
Citations per field
00.5×3.5×
Gerrit Draisma · 1×
Citations per year

Countries citing papers authored by Thomas Björk

Since Specialization
Citations

This map shows the geographic impact of Thomas Björk's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Björk with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Björk more than expected).

Fields of papers citing papers by Thomas Björk

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Björk. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Björk. The network helps show where Thomas Björk may publish in the future.

Co-authors

The 25 scholars most cited alongside Thomas Björk, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Thomas Björk Line = papers co-authored together Thomas Björk links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 35 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Phase I Safety, Pharmacokinetic, and Pharmacodynamic Trial of ZD1839, a Selective Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Five Selected Solid Tumor Types
Hit paper breakdown →
2002683
2
Serum Prostate Specific Antigen Complexed toα1-Antichymotrypsin as an Indicator of Prostate Cancer
Hit paper breakdown →
1993534
3 2013173
4 2010151
5 2001145
6 2007140
7 1994113
8 200887
9 200883
10 199375
11 200068
12 199862
13 199661
14 198757
15 200555
16
Improvements in quality of life and disease-related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in non-small cell lung cancer and other solid tumors.
200340
17 200538
18 199936
19 200735
20 198635

About Thomas Björk

Thomas Björk is a scholar working on Pulmonary and Respiratory Medicine, Rheumatology, Surgery, Oncology and Epidemiology, having authored 35 papers that have together received 2.8k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (25 papers), Prostate Cancer Diagnosis and Treatment (22 papers), Hormonal and reproductive studies (5 papers), Urologic and reproductive health conditions (5 papers), Statistical Methods in Clinical Trials (4 papers), Urinary Bladder and Prostate Research (3 papers), Bladder and Urothelial Cancer Treatments (3 papers) and Urinary Tract Infections Management (3 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (2.0k citations), Oncology (787 citations), Rheumatology (394 citations), Urology (156 citations) and Statistics and Probability (132 citations). Thomas Björk has collaborated with scholars based in Sweden, United States and Finland. Frequent co-authors include Hans Lilja, Per‐Anders Abrahamsson, Abraham T.�K. Cockett, David Ulmert, Anders Christensson, Andrew J. Vickers, Marja‐Terttu Matikainen, Olle Nilsson, Anders Bjartell and Peter T. Scardino. Their work appears in journals such as The Journal of Urology, Urology, Journal of Clinical Oncology, The Prostate and British Journal of Urology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact